Back to Search Start Over

EGFR mutation testing on plasma and urine samples: A pilot study evaluating the value of liquid biopsy in lung cancer diagnosis and management.

EGFR mutation testing on plasma and urine samples: A pilot study evaluating the value of liquid biopsy in lung cancer diagnosis and management.

Authors :
Satapathy S
Singh V
Nambirajan A
Malik PS
Tanwar P
Mehta A
Suryavanshi M
Thulkar S
Mohan A
Jain D
Source :
Current problems in cancer [Curr Probl Cancer] 2021 Dec; Vol. 45 (6), pp. 100722. Date of Electronic Publication: 2021 Mar 03.
Publication Year :
2021

Abstract

Background: Cell free DNA (cfDNA) shed by cancer cells into blood and body fluids is a potential substrate for molecular testing. While plasma is approved for EGFR mutation testing in certain clinical settings, mutation testing on urine is not well explored in lung cancer. In this study, we assess the feasibility and diagnostic accuracy of EGFR mutation analysis on plasma and urine samples.<br />Methods: Matched plasma and urine were collected prospectively from TKI-naïve lung adenocarcinoma (ADCA) patients (Group A) with available tumor tissue. Only plasma was collected from TKI-treated, known EGFR mutant ADCA patients developing TKI resistance (Group B). qPCR (tumor tissue) or digital droplet-PCR (urine/plasma) was performed for exon 19 deletions, exon 21 L858R and exon 20 T790M.<br />Results: Eighty-one patients (60 Group A, 21 Group B) were included. In Group A, EGFR mutations were detected in tissue in 34/60 (57%) patients. Mutations were detected in matched plasma in 24 (24/34, 70.5% sensitivity), and in matched urine in 15 (15/25, 60% sensitivity) of the 34 EGFR mutant cases, with no false positives (100% positive predictive value). Plasma and urine mutation results showed moderate agreement (70%) with a combined sensitivity of 88% (22/25). In Group B, new T790M mutations were detected in plasma in 61% (13/21) patients.<br />Conclusion: Liquid biopsies show moderate sensitivity (plasma > urine) with 100% positive predictive rates for EGFR mutations. Testing of more than one type of liquid biopsy sample increases sensitivity. In TKI-resistant settings, liquid biopsies can obviate need for invasive biopsies in >60% patients.<br /> (Copyright © 2021. Published by Elsevier Inc.)

Details

Language :
English
ISSN :
1535-6345
Volume :
45
Issue :
6
Database :
MEDLINE
Journal :
Current problems in cancer
Publication Type :
Academic Journal
Accession number :
33712318
Full Text :
https://doi.org/10.1016/j.currproblcancer.2021.100722